254 related articles for article (PubMed ID: 20406215)
1. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
2. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Nov; 18(11):937-42. PubMed ID: 18854776
[TBL] [Abstract][Full Text] [Related]
3. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2008 Mar; 48(3):311-21. PubMed ID: 18187595
[TBL] [Abstract][Full Text] [Related]
4. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Dec; 66(6):818-25. PubMed ID: 18823304
[TBL] [Abstract][Full Text] [Related]
5. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
6. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.
Kalliokoski A; Neuvonen M; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2008 Jan; 65(1):78-86. PubMed ID: 17635496
[TBL] [Abstract][Full Text] [Related]
7. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.
Zhang W; He YJ; Han CT; Liu ZQ; Li Q; Fan L; Tan ZR; Zhang WX; Yu BN; Wang D; Hu DL; Zhou HH
Br J Clin Pharmacol; 2006 Nov; 62(5):567-72. PubMed ID: 16796707
[TBL] [Abstract][Full Text] [Related]
8. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
9. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
10. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.
Nassif A; Jia J; Keiser M; Oswald S; Modess C; Nagel S; Weitschies W; Hosten N; Siegmund W; Kühn JP
Radiology; 2012 Sep; 264(3):741-50. PubMed ID: 22771883
[TBL] [Abstract][Full Text] [Related]
11. [Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications].
Takane H
Yakugaku Zasshi; 2011; 131(11):1589-94. PubMed ID: 22041697
[TBL] [Abstract][Full Text] [Related]
12. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
14. Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.
Rohrbacher M; Kirchhof A; Skarke C; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Mar; 7(2):167-76. PubMed ID: 16515396
[TBL] [Abstract][Full Text] [Related]
15. Global analysis of genetic variation in SLCO1B1.
Pasanen MK; Neuvonen PJ; Niemi M
Pharmacogenomics; 2008 Jan; 9(1):19-33. PubMed ID: 18154446
[TBL] [Abstract][Full Text] [Related]
16. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M; Pasanen MK; Neuvonen PJ
Pharmacol Rev; 2011 Mar; 63(1):157-81. PubMed ID: 21245207
[TBL] [Abstract][Full Text] [Related]
17. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Xiang X; Han Y; Neuvonen M; Pasanen MK; Kalliokoski A; Backman JT; Laitila J; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2009 Jun; 19(6):447-57. PubMed ID: 19387419
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
19. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Bachmakov I; Glaeser H; Fromm MF; König J
Diabetes; 2008 Jun; 57(6):1463-9. PubMed ID: 18314419
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
Niemi M; Pasanen MK; Neuvonen PJ
Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
